Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 19/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 19/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 19/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 19/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 19/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 18/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.67 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.67 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7207871 | 0.89 | GABRA1 (0.80) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7478641 | 0.89 | GABRA1 (0.80) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7455510 | 0.88 | GABRA1 (0.79) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7458083 | 0.87 | GABRA1 (0.77) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7479195 | 0.87 | GABRA1 (0.76) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7475583 | 0.85 | GABRA1 (0.74) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7480257 | 0.84 | GABRA1 (0.72) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7249582 | 0.84 | GABRA1 (0.72) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7479860 | 0.83 | GABRA1 (0.83) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1654855 | 0.83 | GABRA1 (0.72) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078874-B2 | Composition and method for treating cognitive impairments in down syndrom subjects | Centre National de la Recherche Scientifique—CNRS (FR) | 2015-07-14 | — | — | US | disclosed |
| US-9078874-B2 | Composition and method for treating cognitive impairments in down syndrom subjects | Centre National de la Recherche Scientifique—CNRS (FR) | 2015-07-14 | — | — | US | disclosed |
| US-20120283248-A1 | COMPOSITION AND METHOD FOR TREATING COGNITIVE IMPAIRMENTS IN DOWN SYNDROM SUBJECTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283248-A1 | COMPOSITION AND METHOD FOR TREATING COGNITIVE IMPAIRMENTS IN DOWN SYNDROM SUBJECTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2012-11-08 | — | — | US | disclosed |
| US-6534505-B2 | Cognition activators, treatment of Alzheimer's disease | MERCK & CO., INC. | 2003-03-18 | — | — | US | disclosed |
| US-6448249-B1 | Substituted 1,2,4-triazolo[3,4-A]phthalazine derivatives as GABAα5 ligands | MERCK SHARP & DOHME LTD. (GB) | 2002-09-10 | — | — | US | disclosed |
| US-6440967-B1 | Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E | MERCK & CO., INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0986562-B1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME (GB) | 2002-08-07 | — | — | EP | disclosed |
| US-20010049439-A1 | Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same | MERCK & CO., INC. | 2001-12-06 | — | — | US | disclosed |
| US-6310203-B1 | Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands | MERCK SHARPE & DOHME LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| US-6200975-B1 | FOR COGNITION ENHANCEMENT THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-0986562-A1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998050385-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283248-A1 | COMPOSITION AND METHOD FOR TREATING COGNITIVE IMPAIRMENTS IN DOWN SYNDROM SUBJECTS | GABRA5, GABRG1, GABRD | GABRA1 8/4885GABRG2 5/4885GABRB3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.